Center/Research Area Affiliations
Long considered a pioneer of modern corneal science, Dr. Dohlman established the Cornea Service and the Cornea Fellowship program at Mass. Eye and Ear in 1960. He is the developer of the Boston Keratoprosthesis (Boston KPro), an artificial cornea that offers hope to many patients for whom a standard corneal transplant is not a viable option. More than 9,000 patients in the United States and in 52 countries worldwide have received a Boston KPro. Dr. Dohlman continues a robust Boston KPro research program with a number of coworkers that addresses simplicity, cost and long-term safety for the device, especially for the developing world.
For a full publication list (330 publications), please see his CV.
1. Kumar R, Dohlman CH, Chodosh J. Oral acetazolamide after Boston keratoprosthesis in Stevens-Johnson syndrome. BMC Res Notes. 2012 Apr 30;5:205. PubMed PMID: 22546532; PubMed Central PMCID:
2. Todani A, Behlau I, Fava MA, Cade F, Cherfan DG, Zakka FR, Jakobiec FA, Gao Y, Dohlman CH, Melki SA. Intraocular pressure measurement by radio wave telemetry. Invest Ophthalmol Vis Sci. 2011 Dec 20;52(13):9573-80. PubMed PMID: 22039243.
3. Cade F, Grosskreutz CL, Tauber A, Dohlman CH. Glaucoma in eyes with severe chemical burn, before and after keratoprosthesis. Cornea. 2011 Dec;30(12):1322-7. PubMed PMID: 22001817.
4. Pujari S, Siddique SS, Dohlman CH, Chodosh J. The Boston keratoprosthesis type II: the Massachusetts Eye and Ear Infirmary experience. Cornea. 2011 Dec;30(12):1298-303. PubMed PMID: 21963861.
5. Behlau I, Mukherjee K, Todani A, Tisdale AS, Cade F, Wang L, Leonard EM, Zakka FR, Gilmore MS, Jakobiec FA, Dohlman CH, Klibanov AM. Biocompatibility and biofilm inhibition of N,N-hexyl,methyl-polyethylenimine bonded to Boston Keratoprosthesis materials. Biomaterials. 2011 Dec;32(34):8783-96.PubMed PMID: 21903257; PubMed Central PMCID: PMC3410931.
View a list of publications on pubmed.gov »